Prediction of sudden cardiac death after myocardial infarction in the beta-blocking era
Heikki V Huikuri1, Jari M Tapanainen, Kai Lindgren
1Division of Cardiology, Department of Medicine, University of Oulu, Oulu, Finland. heikki.huikuri@oulu.fi
Insights
Common arrhythmia risk markers show limited predictive power for sudden cardiac death (SCD) after acute myocardial infarction (AMI) in patients on beta-blocker therapy. Reduced ejection fraction, nonsustained ventricular tachycardia, and abnormal signal-averaged ECG were weakly predictive of SCD.
Area of Science:
- Cardiology
- Clinical Electrophysiology
- Cardiac Risk Assessment
Background:
- Sudden cardiac death (SCD) risk prediction after acute myocardial infarction (AMI) is crucial.
- Contemporary guidelines emphasize medical therapy, including beta-blockers, altering the risk landscape.
- The utility of established arrhythmia risk markers in this modern therapeutic context requires evaluation.
Purpose of the Study:
- To assess the predictive capability of various arrhythmia risk markers for sudden cardiac death (SCD) and total mortality post-acute myocardial infarction (AMI).
- To determine the effectiveness of these markers in patients receiving contemporary guideline-based medical therapy, specifically beta-blockers.
Main Methods:
- A cohort of 700 patients with AMI was followed for mortality outcomes (total mortality, SCD, non-SCD).
- Analyzed risk markers included nonsustained ventricular tachycardia (nsVT), ejection fraction (EF), heart rate variability, baroreflex sensitivity, signal-averaged ECG (SAECG), QT dispersion, and QRS duration.
- Ninety-seven percent of patients received beta-blocker therapy at discharge.
Main Results:
- Over a mean follow-up of 43 months, 22 SCDs and 37 non-SCDs occurred.
- All analyzed arrhythmia risk variables differed significantly between survivors and non-SCD groups.
- Reduced EF, nsVT, and abnormal SAECG showed weak prediction for SCD (8-13% accuracy), while autonomic and standard ECG markers were not significant predictors.
Conclusions:
- Established arrhythmia risk markers, especially autonomic and standard ECG parameters, possess limited predictive power for SCD in the current beta-blocking era post-AMI.
- Risk stratification for SCD in post-MI patients on optimal medical therapy may require novel approaches beyond traditional markers.
Objectives:
This study assessed the predictive power of arrhythmia risk markers after an acute myocardial infarction (AMI).
Background:
Several risk variables have been suggested to predict the occurrence of sudden cardiac death (SCD), but the utility of these variables has not been well established among patients using medical therapy according to contemporary guidelines.
Methods:
A consecutive series of 700 patients with AMI was studied. The end points were total mortality, SCD, and nonsudden cardiac death (non-SCD). Nonsustained ventricular tachycardia (nsVT), ejection fraction (EF), heart rate variability, baroreflex sensitivity, signal-averaged electrocardiogram (SAECG), QT dispersion, and QRS duration were analyzed (n = 675). Beta-blocking therapy was used by 97% of the patients at discharge and by 95% at one and two years after AMI.
Results:
During a mean (+/-SD) follow-up of 43 +/- 15 months, 37 non-SCDs (5.5%) and 22 SCDs (3.2%) occurred. All arrhythmia risk variables differed between the survivors and those with non-SCD (e.g., the standard deviation of N-N intervals was 98 +/- 32 vs. 74 +/- 21 ms [p < 0.001] and the QRS duration was 103 +/- 22 vs.89 +/- 16 ms [p < 0.001]). Sudden cardiac death was weakly predicted only by reduced EF (<0.40; p < 0.05), nsVT (p < 0.05), and abnormal SAECG (p < 0.05), but not by autonomic markers or standard ECG variables. The positive predictive accuracy of EF, nsVT, and abnormal SAECG as predictors of SCD was relatively low (8%, 12%, and 13%, respectively).
Conclusions:
The common arrhythmia risk variables, particularly the autonomic and standard ECG markers, have limited predictive power in identifying patients at risk of SCD after AMI in the beta-blocking era.
Related Concept Videos
01:22Heart Failure Drugs: β-Blockers
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
01:28Antihypertensive Drugs: Types of β-Blockers
01:25Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers